Status:
COMPLETED
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Gastrointestinal Stromal Tumors
Eligibility:
All Genders
20-74 years
Phase:
PHASE2
Brief Summary
This is a extension study of CSTI571B1201 study
Eligibility Criteria
Inclusion
- \- Patients who completed the CSTI571B1201 study
Exclusion
- \-
- Other protocol-defined inclusion / exclusion criteria may apply.
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00237172
Start Date
September 1 2002
Last Update
May 1 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.